A primary function of the immune system is to determine which cells or substances are self or non-self. The immune system only makes enough white blood cells to fight non-self antigens present in the body. After an at­tack, the immune system must slow down. It does this through the use of checkpoints.
Co-inhibitory checkpoints keep the immune system “in check,” preventing an attack on normal cells by using regulatory T-cells and other mechanisms. When the correct proteins and cell receptors connect, a series of signals is sent to the immune sys­tem to slow down once an immune response is finished. Three checkpoint receptors that slow down the immune system have been identified for their roles in cancer treatment: CTLA4, PD-1 and PD-L1.
PD-1 (programmed cell death protein 1) is a receptor involved with telling T-cells to die and to reduce the death of regulatory T-cells (suppressor T-cells). Both slow down an immune response. PD-1 can tell the immune system to slow down only if it connects with PD-L1.
   Anti-PD-1 antibody LVGN3616 blocks the connection between PD-1 and PD-L1, allow for the continued or increased production of T-cells and enable them to continue fighting cancer.
For more scientific rationale, please visit PD-1.

   Our Progress:
We are conducting Phase I trials of LVGN3616 in combination studies in China and the USA.
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: clinical@lyvgen.com or send us a message.